Agrawal, A., Hussain, K. S., & Kumar, A. (2020). Minor blood group incompatibility due to blood groups other than Rh(D) leading to hemolytic disease of fetus and newborn: a need for routine antibody screening during pregnancy. Intractable & Rare Diseases Research, 9(1), 43–47. doi.org/10.5582/irdr.2019.01094.
Atalah, E., Castillo, C., Castro, R., & Aldea, A. (1997). Propuesta de un nuevo estándar de evaluación nutricional en embarazadas. Revista Medica de Chile, 125(12), 1429–1436. https://pubmed.ncbi.nlm.nih.gov/9609018/.
Bennardello, F., Coluzzi, S., Curciarello, G., Todros, T., & Villa, S. (2015). Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. Blood Transfusion, 13(1), 109–134. doi.org/10.2450/2014.0119-14.
Bichler, J., Schöndorfer, G., Pabst, G., & Andresen, I. (2003). Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. BJOG: An International Journal of Obstetrics and Gynaecology, 110(1), 39–45. doi.org/10.1046/j.1471-0528.2003.02158.x.
Clausen, F. B., & Hellberg, Å. (2020). External quality assessment of noninvasive fetal RHD genotyping. Vox Sanguinis, 115(5), 466–471. doi.org/10.1111/vox.12908
Darlington, M., Carbonne, B., Mailloux, A., Brossard, Y., Levy-Mozziconacci, A., Cortey, A., et al. (2018). Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women. BMC Pregnancy and Childbirth, 18(1), 496. doi.org/10.1186/s12884-018-2114-5.
Eklund, J., Hermann, M., Kjellman, H., & Pohja, P. (1982). Turnover rate of anti-D IgG injected during pregnancy. BMJ, 284(6319), 854–855. doi.org/10.1136/bmj.284.6319.854.
Finck, R., Lui-Deguzman, C., Teng, S. M., Davis, R., & Yuan, S. (2013). Comparison of a gel microcolumn assay with the conventional tube test for red blood cell alloantibody titration. Transfusion, 53(4), 811–815. doi.org/10.1111/j.1537-2995.2012.03793.x.
Flesiopoulou, I., Pouliakis, A., Politou, M., Dourouki, A., Damaskos, C., Koutsouri, T., et al. (2020). Red Blood Cell Alloantibody Titration - Does the Titration Method Matter? Clinical Laboratory, 66(6), 1–8. doi.org/10.7754/Clin.Lab.2019.191021.
Geaghan, S. M. (2011). Diagnostic laboratory technologies for the fetus and neonate with isoimmunization. Seminars in Perinatology, 35(3), 148–154. doi.org/10.1053/j.semperi.2011.02.009.
Guiver, J., & Wright, G. (2019). Routine antenatal management later in pregnancy. Obstetrics, Gynaecology & Reproductive Medicine, 29(6), 164–169. doi.org/10.1016/j.ogrm.2019.03.003.
Harmening, D. (2019). Modern blood banking and transfusion practices (D. Harmening (ed.); 7th ed.). F. A. Davis Company.
Irving, C., Crennan, M., & Vanniasinkam, T. (2017). Can serological methods help distinguish between prophylactic and alloimmune anti-D? Transfusion Medicine, 27(5), 362–368. doi.org/10.1111/tme.12420.
Krishnan, V., Shenoy, V., Sunny, S., Thambiran, R., Keezhattoor, D., Namdeo, S., et al. (2020). Defining critical antibody titre in column agglutination method to guide fetal surveillance. Transfusion and Apheresis Science, 59(3), 102732. doi.org/10.1016/j.transci.2020.102732.
MacKenzie, I. Z., Roseman, F., Findlay, J., Thompson, K., Jackson, E., Scott, J., et al. (2006). The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin. BJOG: An International Journal of Obstetrics and Gynaecology, 113(1), 97–101. doi.org/10.1111/j.1471-0528.2005.00789.x.
Mayekar, R. V., Paradkar, G. V., Bhosale, A. A., Sachan, R., Beeram, S., Anand, A. R., et al. (2020). Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial. Obstetrics & Gynecology Science, 63(3), 315–322. doi.org/10.5468/ogs.2020.63.3.315.
Moise, K. J. (2008). Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Seminars in Fetal and Neonatal Medicine, 13(4), 207–214. doi.org/10.1016/j.siny.2008.02.007.
Novaretti, M. C. Z., Jens, E., Pagliarini, T., Bonifacio, S. L., Dorlhiac-Llacer, P. E., & Chamone, D. A. F. (2003). Comparison of conventional tube test with diamed gel microcolumn assay for anti-D titration. Clinical and Laboratory Haematology, 25(5), 311–315. doi.org/10.1046/j.1365-2257.2003.00540.x.
Pegoraro, V., Urbinati, D., Visser, G. H. A., Di Renzo, G. C., Zipursky, A., Stotler, B. A., et al. (2020). Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children. PLOS ONE, 15(7), e0235807. doi.org/10.1371/journal.pone.0235807.
Ryczek, E., White, J., & Carolan-Rees, G. (2020). Implementation of high-throughput non-invasive prenatal testing for fetal RHD genotype testing in England: Results of a cross-sectional survey of maternity units and expert interviews. Transfusion Medicine (Oxford, England), 30(4), 287–294. doi.org/10.1111/tme.12702.
Schmidt, L. C., Cabral, A. C. V., Faria, M. A., Monken, F., Tarazona-Santos, E., & Martins, M. L. (2014). Noninvasive fetal RHD genotyping from maternal plasma in an admixed Brazilian population. Genetics and Molecular Research, 13(1), 799–805. doi.org/10.4238/2014.February.7.1.
Sinclair, C. J., Brooks, W., & Genereux, M. G. (2008). Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin. Biologicals, 36(4), 256–262. doi.org/10.1016/j.biologicals.2008.02.003.
Szkotak, A. J., Lunty, B., Nahirniak, S., & Clarke, G. (2016). Interpretation of pretransfusion testing in obstetrical patients who have received antepartum Rh immunoglobulin prophylaxis. Vox Sanguinis, 110(1), 51–59. doi.org/10.1111/vox.12302.
Tiblad, E., Wikman, A., Rane, A., Jansson, Y., & Westgren, M. (2012). Pharmacokinetics of 250 μg anti-D IgG in the third trimester of pregnancy: an observational study. Acta Obstetricia et Gynecologica Scandinavica, 91(5), 587–592. doi.org/10.1111/j.1600-0412.2012.01377.x.
Woelfer, B., Schuchter, K., Janisiw, M., Hafner, E., Philipp, K., & Panzer, S. (2004). Postdelivery levels of anti-D IgG prophylaxis in D- mothers depend on maternal body weight. Transfusion Practice, 44(4), 512–517. doi.org/10.1111/j.1537-2995.2004.03287.x.